Online inquiry

IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10464MR)

This product GTTS-WQ10464MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Canine B-cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10464MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5855MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ10475MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ8189MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ4507MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ8569MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ8895MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ3691MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ10529MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3015014
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW